Caris Life Sciences (CAI) on Thursday reported first-quarter results with revenue rising sharply from last year while losses narrowed, driven by strong growth in molecular profiling services.
Total revenue increased to $216.2 million in the first quarter of 2026 from $120.9 million in the same period last year.
The company posted an operating income of $5.3 million, compared with an operating loss of $58.0 million a year earlier. Net loss narrowed to $0.5 million, or $0.00 per share, from $102.6 million, or $3.57 per share, in the first quarter of 2025.
CAI is currently trading after hours at $16.94, down $2.90 or 14.62 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.